GSK, Zymeworks
VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage ...
Zymeworks Inc. (NYSE:ZYME – Get Free Report) has been given a consensus rating of “Moderate Buy” by the seven research firms ...
Zymeworks Inc. Appoints Oleg Nodelman to Board of Directors as Part of Ongoing Board Renewal Process
The company is advancing a robust pipeline of product candidates, including zanidatamab, which has received FDA accelerated approval for a significant medical indication, positioning Zymeworks for ...
Zymeworks Inc. VANCOUVER, British Columbia, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel ...
Investment analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Zymeworks in a note issued to ...
Zymeworks Inc., a clinical-stage biotechnology company based in Vancouver, is focused on developing novel biotherapeutics for challenging diseases such as cancer and autoimmune conditions.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results